Sign up USA
Proactive Investors - Run By Investors For Investors

Apricus Biosciences inks exclusive European collaboration for Vitaros with Novartis unit

Apricus Biosciences inks exclusive European collaboration for Vitaros with Novartis unit

Apricus Biosciences (NASDAQ:APRI) said Wednesday it has signed an exclusive collaboration to market Vitaros, an erectile dysfunction medication, with Novartis AG’s (NYSE:NVS) Sandoz division.

According to the deal, Sandoz will pay Apricus Biosciences up to 21 million euros, or $27.4 million. The payment will be divided into a fixed upfront payment and specific commercial milestones, as well as double-digit royalties on net sales.

"We are very excited about this major European collaboration with such an important international pharmaceutical company as Sandoz,” chief executive Bassam Damaj said in a statement.

"This is yet another important milestone in our strategy to make Vitaros available worldwide and the successful continuation of the execution of our commercialization strategy of Vitaros."

Apricus' drug Vitaros is approved in Canada and the specialty pharmaceutical company has also filed for marketing approval in the United States.

San Diego, California-based Apricus already licensed the Canadian marketing rights of Vitaros to Abbott Laboratories (NYSE:ABT) in January and the Italian marketing rights to Bracco SpA in 2010.

Apricus, founded in 1987 and with about 35 employees, makes drug candidates based on its NexACT delivery technology.

The NexACT technology is designed to enhance the delivery of an active drug to improve therapeutic outcomes and cut down systemic side effects associated with oral and injectable medications.

Shares of the company were up 4.68 percent at $3.58 each on the Nasdaq Wednesday afternoon.

Register here to be notified of future APRI Company articles
View full APRI profile View Profile

Apricus Biosciences Timeline

Related Articles

picture of drug lab
February 07 2017
Amryt Pharma’s strategy to acquire, in-license and then develop drugs for hard to treat, so-called orphan diseases has been seeing some good progress.
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use